RT Journal Article
SR Electronic
T1 Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major SARS-CoV-2 variants in a chronically infected immunocompromised patient
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.21.22272673
DO 10.1101/2022.03.21.22272673
A1 Burel, Emilie
A1 Colson, Philippe
A1 Lagier, Jean-Christophe
A1 Levasseur, Anthony
A1 Bedotto, Marielle
A1 Lavrard, Philippe
A1 Fournier, Pierre-Edouard
A1 La Scola, Bernard
A1 Raoult, Didier
YR 2022
UL http://medrxiv.org/content/early/2022/03/23/2022.03.21.22272673.abstract
AB Genetic recombination is a major evolutionary mechanism among RNA viruses, and it is common in coronaviruses, including those infecting humans. A few SARS-CoV-2 recombinants have been reported to date whose genome harbored combinations of mutations from different mutants or variants, but a single patient’s sample was analyzed, and the virus was not isolated. Here, we re-port the gradual creation of a hybrid genome of B.1.160 and Alpha variants in a lymphoma patient chronically infected for 14 months, and we isolated the recombinant virus. The hybrid genome was obtained by next-generation sequencing, and recombination sites were confirmed by PCR. This consisted of a parental B.1.160 backbone interspersed with two fragments, including the spike gene, from an Alpha variant. Analysis of seven sequential samples from the patient decoded the recombination steps, including the initial infection with a B.1.160 variant, then a concurrent infec-tion with this variant and an Alpha variant, the generation of hybrid genomes, and eventually the emergence of a predominant recombinant virus isolated at the end of the patient’s follow-up. This case exemplifies the recombination process of SARS-CoV-2 in real life, and it calls for intensifying genomic surveillance in patients coinfected with different SARS-CoV-2 variants, and more gener-ally with several RNA viruses, as this may lead to the creation of new viruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future program managed by the National Agency for Research (ANR) (Mediterranee-Infection 10-IAHU-03), by the Region Provence Alpes Cote d Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d'Innovation Mutualisees Mediterranee Infection) (FEDER PA 0000320 PRIMMI), and by the French Ministry of Higher Education, Research and Innovation (ministere de l'Enseignement superieur, de la Recherche et de l'Innovation) and the French Ministry of Solidarity and Health (Ministere des Solidarites et de la Sante).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the ethics committee of University Hospital Institute (IHU) Mediterranee Infection (No. 2022-008). Access to the patient biological and registry data issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hopitaux de Marseille (APHM) and was recorded in the European General Data Protection Regulation registry under number RGPD/APHM 2019-73.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset generated and analyzed during the current study is available in the GISAID sequence database (https://www.gisaid.org/). https://www.gisaid.org/